




Contents lists available at [ScienceDirect](#)
**Journal of Mass Spectrometry and
Advances in the Clinical Lab**

journal homepage: www.sciencedirect.com/journal/journal-of-mass-spectrometry-and-advances-in-the-clinical-lab



Corrigendum to “Analytical validation of protein biomarkers for risk of spontaneous preterm birth” [Clin. Mass Spectrom. 3 (2017) 25–38]

Chad Bradford^a, Rob Severinsen^a, Trina Pugmire^a, Matison Rasmussen^a, Kathryn Stoddard^a, Yuta Uemura^a, Spencer Wheelwright^a, Marija Mentinova^b, Daniel Chelsky^b, Stephen W. Hunsucker^c, Paul Kearney^c, Durlin Hickok^a, Tracey C. Fleischer^a, Ilia Ichetovkin^a, J. Jay Boniface^{a,*}, Gregory C. Critchfield^a, John M. Peltier^a

^a Sera Prognostics, Inc., 2749 East Parleys Way, Suite 200, Salt Lake City, UT 84109, USA

^b Caprion Biosciences, 201 Avenue Président Kennedy, Suite 3900, Montréal, Québec H2X 3Y7, Canada

^c Integrated Diagnostics, Inc., 219 Terry Avenue North, Suite 110, Seattle, WA 98101, USA

The authors wish to include two sentences in the Experimental section of the above mentioned paper. In Section 2.1.1, following the last sentence of the first paragraph, which reads “The PAPR study followed the Good Clinical Practice guidelines issued by the International Conference on Harmonisation.”, please insert “Participating women

provided voluntary, informed consent. The original study protocols as well as these secondary analyses were approved by the representative institutional review boards.”.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.clinms.2017.06.002>.

* Corresponding author at: Sera Prognostics, Inc., Salt Lake City, UT, USA.

E-mail address: jboniface@seraprognostics.com (J.J. Boniface).

<https://doi.org/10.1016/j.jmsacl.2022.07.007>